1. Overview of included studies.
| Duration of study | Number randomised | Severity of participants | Dose of aclidinium | Frequency of aclidinium | |
| ACCLAIM/COPD I | 52 weeks | 843 | Moderate to severe (GOLD) |
200 µg | Once daily |
| ACCLAIM/COPD II | 52 weeks | 804 | Moderate to severe (GOLD) |
200 µg | Once daily |
| ACCORD COPD I | 12 weeks | 561 | Moderate to severe (GOLD) |
200, 400 µg | Twice daily |
| ACCORD COPD II | 12 weeks | 544 | Moderate to severe (GOLD) |
200, 400 µg | Twice daily |
| ACLIFORM | 24 weeks | 1729 | Moderate to severe (GOLD) |
400 µg | Twice daily |
| ATTAIN | 24 weeks | 828 | Moderate to severe (GOLD) |
200, 400 µg | Twice daily |
| AUGMENT COPD | 24 weeks | 1692 | Moderate to severe (GOLD) |
400 µg | Twice daily |
| Beier 2013 | 6 weeks | 414 | Moderate to severe (GOLD) |
400 µg | Twice daily |
| Chanez 2010 | 4 weeks | 464 | Moderate to severe (ATS) |
25, 50, 100, 200, 400 µg |
Once daily |
| Maltais 2011 | 6 weeks | 181 | Moderate to severe (GOLD) |
200 µg | Once daily |
| NCT01572792 | 28 weeks | 921 | Moderate to severe (GOLD) |
400 µg | Twice daily |
| Sliwinski 2010 | 4 weeks | 566 | Moderate to severe | 200 µg | Once daily |